Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SKB264 with or without KL-A167 in previously untreated unresectable locally advanced, recurrent, or metastatic HER2-negative breast cancer
CTR20221755Phase 2Completed
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Sep 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, tagitanlimab in breast cancer, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Sep 2022; status: completed.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20221755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221755.